Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Margonis, GA; Wang, JJ; Boerner, T; Moretto, R; Buettner, S; Andreatos, N; Gagnière, J; Wagner, D; Løes, IM; Bergamo, F; Pietrantonio, F; Scartozzi, M; Spallanzani, A; Vincenzi, B; Antoniou, E; Pikoulis, E; Sartore-Bianchi, A; Stasinos, G; Sasaki, K; Pawlik, TM; Orlandi, A; Pella, N; Fitschek, F; Kaczirek, K; Dupré, A; Pozios, I; Beyer, K; Kornprat, P; Aucejo, FN; Burkhart, R; Weiss, MJ; Lønning, PE; Poultsides, G; Cremolini, C; Kreis, ME; D'Angelica, M.
Hepatectomy versus systemic therapy for liver-limited BRAF V600E-mutated colorectal liver metastases: multicentre retrospective study.
Br J Surg. 2024; 111(7):
Doi: 10.1093/bjs/znae176
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Kornprat Peter
- Wagner Doris
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: To date, only two studies have compared the outcomes of patients with liver-limited BRAF V600E-mutated colorectal liver metastases (CRLMs) managed with resection versus systemic therapy alone, and these have reported contradictory findings. METHODS: In this observational, international, multicentre study, patients with liver-limited BRAF V600E-mutated CRLMs treated with resection or systemic therapy alone were identified from institutional databases. Patterns of recurrence/progression and overall survival were compared using multivariable analyses of the entire cohort and a propensity score-matched cohort. RESULTS: Of 170 patients included, 119 underwent hepatectomy and 51 received systemic treatment. Surgically treated patients had a more favourable pattern of recurrence with most recurrences limited to a single site, whereas diffuse progression was more common among patients who received systemic treatment (19 versus 44%; P = 0.002). Surgically treated patients had longer median overall survival (35 versus 20 months; P < 0.001). Hepatectomy was independently associated with better OS than systemic treatment alone (HR 0.37, 95% c.i. 0.21 to 0.65). In the propensity score-matched cohort, surgically treated patients had longer median overall survival (28 versus 20 months; P < 0.001); hepatectomy was independently associated with better overall survival (HR 0.47, 0.25 to 0.88). CONCLUSION: BRAF V600E mutation should not be considered a contraindication to surgery for patients with resectable, liver-only CRLMs.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Liver Neoplasms - secondary, genetics, surgery, mortality
- Hepatectomy - methods
- Colorectal Neoplasms - genetics, pathology
- Proto-Oncogene Proteins B-raf - genetics
- Male - administration & dosage
- Female - administration & dosage
- Retrospective Studies - administration & dosage
- Middle Aged - administration & dosage
- Aged - administration & dosage
- Mutation - administration & dosage
- Propensity Score - administration & dosage
- Neoplasm Recurrence, Local - genetics
- Adult - administration & dosage
- Treatment Outcome - administration & dosage